In silico drug discovery refers to a combination of computational techniques that augment our ability to discover drug compounds from compound libraries. Many such techniques exist, including virtual high-throughput screening (vHTS), high-throughput screening (HTS), and mechanisms for data storage and querying. However, presently these tools are often used independent of one another. In this chapter, we describe a new multimodal in silico technique for the hit identifi cation and lead generation phases of traditional drug discovery. Our technique leverages the benefi ts of three independent methods-virtual high-throughput screening, high-throughput screening, and structural fi ngerprint analysis-by using a fourth technique called topological data analysis (TDA). We describe how a compound library can be independently tested with vHTS, HTS, and fi ngerprint analysis, and how the results can be transformed into a topological data analysis network to identify compounds from a diverse group of structural families. This process of using TDA or similar clustering methods to identify drug leads is advantageous because it provides a mechanism for choosing structurally diverse compounds while maintaining the unique advantages of already established techniques such as vHTS and HTS.
Introduction
In silico drug discovery refers to the use of computati onal technology to advance the process of drug discovery. More generally, in silico refers to a testing environment, in contrast to in vitro and in vivo, named after silicon-based computer chips. In silico drug discovery methods include basic processes such as database storage and querying and also technically advanced methods such as virtual ligand screening and topological data analysis [ 1 ] . These methods accelerate various steps in the drug discovery process, ranging from identifi cation, 3D-reconstruction, and modeling of protein targets to identifi cation of promising hits and lead drug compounds [ 2 ] . Empirically, in silico drug discovery, or as some refer to it, computer-aided drug design (CADD), has had numerous successes, such as aiding in the discovery of drugs against human immunodefi ciency virus (HIV) including ritonavir and indinavir, as well as captopril, an angiotensin-converting enzyme (ACE) inhibitor for treating hypertension [ 3 -5 ] .
The rise in popularity of in silico drug discovery is correlated with the advent in computational power, the advancement of computational methods, and the failures of traditional drug discovery methods. Modern drug discovery on average requires 12.5 years and $1 billion for the launch of a technically successful drug, which is a highly prohibitive amount for most groups to pursue [ 6 ] . As a result, fewer entrants participate in drug discovery and those that do often necessitate exorbitant drug prices to recoup the costs of development. Fortunately, the improvement of computational speed and techniques has paved the way for in silico applications to lower the threshold and costs for participating in drug discovery and to accelerate the process of launching a successful drug. Modern processing power is constantly improving and current parallel processing systems can perform structure-based screening on more than 100,000 compounds per day [ 7 ] . We can only expect that as computational power and techniques continue to expand, the time and cost required to perform in silico drug discovery will be an even greater advantage when compared to traditional lead generation.
In this chapter, we describe a specifi c in silico approach to drug discovery that harnesses and combines the power of three popular techniques-virtual ligand screening, high-throughput screening (HTS), and fi ngerprint structural analysisby using a fourth technique called topological data analysis (TDA), with the goal of identifying promising drug compounds from compound libraries, serving as a replacement to the hit identifi cation stage and the subsequent lead generation stage of traditional drug discovery ( Fig. 15.1 ) . These methods will be employed once a biological target (receptor, enzyme, ion channel, etc.) has already been identifi ed and validated.
The goal of the hit identifi cation stage of drug discovery is to ide ntify a subset of compounds from a much larger compound library that meet a success criterion against a certain target [ 8 ] . Hit identifi cation is currently most often performed by high-throughput screening (HTS), a technique in which hundreds of thousands of compounds are assayed by robotics to determine which have the most signifi cant activity against the target. The libraries that are screened include random libraries, thematic libraries (focused toward the biochemical function of the target), and knowledge-based libraries (focused toward compounds that possess characteristics known to be required of a lead) [ 8 ] . These HTS strategies have been extremely successful and adept at identifying potent leads and eventually successful drugs, and in fact, this process has initiated most approved drugs on the market. However, the current limitations of high-throughput screening for hit identifi cation are cost, time required, and low hit rate. In a direct comparison of HTS to computer-aided drug discovery, researchers demonstrated a hit rate of 34.8 % (127 of 365 compounds) when using CADD versus only 0.021 % (81 of 400,000) when using HTS, representing a 1700-fold enrichment of the hit rate when using computational methods [ 9 ] . Our approach will offer a means of combining the unique advantages of HTS and virtual screening into a single workfl ow.
After hit identifi cati on, the next step in drug discovery is "hit-to-lead" (H2L) or lead generation. A lead is a hit that represents a compound series with the potential (signifi ed by its potency, pharmacokinetic properties, selectivity, and low toxicity) to become a technically successful drug [ 8 ] . Lead generation takes into account practical aspects of the compound, such as its ability to be synthesized at large scales for low costs, availability of intellectual property, low cytotoxicity, favorable pharmacokinetics, and high selectivity amongst other characteristics.
This chapter focus on a novel approach to in silico drug discovery that aims to improve the two aforementioned stages: hit identifi cation and lead generation, via the use of combined computational methods. The compounds that are identifi ed must then undergo the later stages of drug discovery, which include lead optimization and concept testing ( Fig. 15.1 ) .
Our pathway for early stage lead generation will follow four stages: Stage 1 is virtual high throughput screening (vHTS), Stage 2 is traditional high throughput screening (HTS), Stage 3 is fi ngerprint analysis of small molecules, and Stage 4 will integrate the results with topological data analysis (TDA). Stage 1 and 2 are commonly used techniques for hit generation. In Stage 3, we will use PubChem's fi ngerprints to harvest complex, granular structural information about our compounds. Finally, in Stage 4 we will create a topological network of our compound library based on their structural similarities as derived from molecular fi ngerprints (Stage 3). The topological network will serve as a framework for more intelligent hit selection using the results from Stages 1 and 2 ( Fig. 15.2 ).
Drug Discovery Techniques

Virtual Ligand Screening
Virtual ligand screening or virtual high-throughput screening (vHTS) is an in silico approach to drug discovery which involves the computational simulation of compoundtarget binding to determine which compounds have the best binding potential.
High-throughput Screening (HTS)
High-throughput screening is a robotic approach for scr eening thousands of compounds in short time frames to obtain an initial sense of their viability.
Fingerprint Structural Analysis
Fingerprints are a collection of binary variables that describe structural features of a compound, which allow researchers to perform multivaria ble data analysis.
Topological Data Analysis (TDA)
Topological data analysis is a mathematical technique for studying relationships among data points in high dimensional datasets through the creation of similarity networks [ 10 -13 ] .
Choosing a Compound Library
The fi rst step of this methodology requires the researcher to have access to a library of small molecule compounds, which will serve as the basis for the remainder of the techniques. The compound library can consist of any number of compounds, 
Stage I: Virtual High Throughput Screening (vHTS)
Structure-based drug design (SBDD) is a general term for drug discovery techniques that utilize the 3-dimensional structure of a target to predict and optimize the activity of drug compounds. A specifi c method of SBDD is virtual scree ning or virtual high throughput screening (vHTS), which is a technique for computationally simulating the drug-target interactions of compounds to quantify their effect potential [ 14 ] . Its objective is to quickly identify "hits" or promising compounds within a larger library, which makes it comparable to traditional high throughput screening. However, its comparative advantage is that all of the simulations can be done computationally rather than experimentally, resulting in large savings in time and cost. The primary distinction to be made within vHTS is between a ligand-based and receptor-based approach [ 15 ] . In the ligand-based approach, a particular ligand of interest is used to identify similar ligands, using techniques such as similarity searching, fi ngerprint analysis, and quantitative structure-activity relationships (QSAR) . In this method, the objective is to start with a potentially promising ligand and fi nd others that share similar qualities. In contrast, the receptor-based approach starts with a 3D target protein of interest and attempts to identify potential ligands based on their ability to successfully interact with the target, through computational docking and scoring algorithms. We suggest the receptor-based approach of vHTS because it allows one to discover a broad diversity of ligands, as the identifi cation methods are based on their relationship to the target rather than their similarity to each other.
The fi rst step in vHTS is to select a docking program to run the virtual screen. Several such programs are publicly available including AutoDock (Scripps Research Institute, San Diego, CA), DOCK (UCSF, San Francisco, CA), LigandFit [ 16 ] , and FlexX (Universitat Hamburg, Hamburg, Germany). We have personally employed AutoDock Vina as it offers comprehensive tools and is freely available for academic purposes.
Once a docking program is chosen and installed, the next process is to prepare the protein target, which involves two sub-steps: (a) resolving the 3D structure, and (b) choosing a binding site for docking. Owing to the advances in experimental methods such as nuclear magnetic resonance (NMR) spectroscopy, X-ray crystallography, and electron microscopy (EM), we now know the 3D structures of thousands of protein targets [ 17 ] . The vast majority of these structures are deposited in the Protein Data Bank (PDB), which contains structures ranging from protein fragments to large macromolecules. As of 2007, the PDB included over 53,000 protein structures with more than 8000 new structures being added each year [ 17 ] . However, if the 3D structure of a protein of interest has not yet been resolved, there are comparative homology modeling techniques, which involve sequence alignment and construction of missing coordinates, to predict its 3D structure [ 3 ] . Although not perfect, these methods are well-described and empirically successful [ 18 ] . Once the 3D structure is available, the researcher must determine the optimal binding site on the target for the program to use in its docking simulations. Binding sites are usually chosen based on either known biological information about the mechanism of the protein or on cocrystal structures that have a known ligand [ 3 ] . However, computational programs, including POCKET and SURFNEt also exist to discover novel binding sites within a target using techniques such as locating concave invaginations and evaluating protein dynamics [ 3 ] . Now that a docking program, compound libra ry, and protein target are all chosen and prepared, the remaining steps involve running the vHTS on your library of compounds. When operating on the docking software, there are a few prerequisite steps. First, the docking site (active site) of the target protein needs to be defi ned by an accurate "grid box" that encompasses the entire surface of the binding site ( Fig. 15.3 ) . Second, the structure fi les of the target protein and screening compounds need to be formatted according to the requirements of the docking software. Third, requisite information for both the target protein and the virtual compound library need to be appropriately recorded in the confi guration fi le of the docking software. With these steps completed, the virtual screening should proceed without complication.
The output of the vHTS should be a list of the compounds and their respective scores (often presented as binding energies) as it relates to their binding effi cacy. The compounds with the best scores represent the "hits" from the vHTS, and any number of them can be tested experimentally to verify their binding activity. Although it is suffi cient to proceed with these hits to the "hit-to-lead" stage of drug discovery, we will instead save these scores as Column 1 in a datasheet, which we will use later when we integrate the results of the three stages of analysis.
Stage II: Traditional High-Throughput Screening (HTS)
The introduction of automated high-throughput screening in the 1990s represented a signifi cant milestone in the fi eld of drug discovery. For perhaps the fi rst time, large compound libraries, containing hundreds of thousands of compounds, could be quickly and effi ciently screened by robots in the order of days to reveal a smaller subset of compounds with the highest potential for activity. By doing so, researchers could quickly identify a group of high-potential compounds to progress to the lead generation stage of discovery. This method further optimized the drug discovery process by eliminating the need for extensive "hit-to-lead" translation, as most of these compounds were already ready for large-scale pharmaceutical development [ 8 ] . These screenings were traditionally performed on large diversity-driven libraries, where the focus was on quantity of compounds rather than likelihood of activity. However, as discussed previously, researchers are currently trending toward using thematic libraries that are built with prior knowledge of the target using combinatorial chemistry. High-throughput screening is the most empirically successful method of lead generation, as almost every new drug compound has emerged through a process involving HTS [ 8 ] . Examples are numerous and include Merck Research Laboratories' discovery of diketoacids, a novel HIV-suppressing class of compounds which block viral integration of HIV-1 integrase and Harvard University's discovery of monastrol, an anticancer agent that blocks mitosis by inhibiting kinesin Eg5, after screening the Diverset E (Chembridge Corporation, San Diego, CA) library of more than 16,000 compounds [ 8 ] .
Although many researchers are now favoring virtual high-throughput screening to traditional high-throughput screening because of the improved speed, lower cost, and increased effi ciency, there are still several unique comparative benefi ts to HTS, which help it remain as an important step in the drug discovery process. First, HTS allows you to identify compound hits without signifi cant prior knowledge about the target, such as binding sites, compound affi nities, or structural characteristics. This advantage allows researchers to identify hits for targets where the 3D structure is unresolved or for targets that are not mechanistically understood. Second, improvements in HTS effi ciency and assay quality will improve the hit-fi nding ability of HTS compared to vHTS [ 19 ] . Newer assays are being developed to optimize sensitivity, thereby increasing the ability to detect weakly active compounds, which could become very successful future leads. Although favoring sensitivity will slightly increase the false positive rate, these falsely positive compounds can be discarded in future stages of the drug discovery process.
We briefl y describe the steps of our high-throughput screens. We begin with a primary screen that tests our entire compound library. As there are thousands compounds to test at this stage, the screening is performed on the main reporter cell line at only one concentration per compound. Since the majority of compounds in the library will be negative hits, this step serves to quickly narrow down the library to only the most promising compounds based on their effi cacy in the single tested concentration. Then a subset of compounds, now in the range of hundreds to thousands, will be tested in a secondary screen (Fig. 15.4 ). For this step, an approach called quantitative high throughput screening (qHTS) can be applied, in which each compound is tested at a series of concentrations on both the main reporter cell line and a counter-screen reporter cell line, usually used to control for undesired effects (e.g., cytotoxicity) [ 20 ] . The results of the secondary screen are a dose-activity curve for each compound at the various tested concentrations.
As before, these results can be independently used to advance certain compounds to the lead optimization stage. However, for our methodology, we will save the secondary screen assay results from one specifi c concentration as a "percent-inhibition" value into a new column (Column 2) in the same spreadsheet as before. These two columns will be utilized in the fourth stage of our drug discovery process, when we use topological data analysis to integrate the results.
Stage III: PubChem Fingerprint Analysis
In the fi nal stage of this process, we use structural information about compounds to further enhance our ability to identify hits. The major advancement in the use of chemical and structural information to assist with drug discovery was quantitative structure-activity relationship (QSAR) models, which uses statistical models to predict how different physicochemical properties of chemical substances affect biological activity [ 21 ] . The earliest example of QSAR dates back to 1893, when Charles Richet described a novel relationship between the solubility of compounds and their toxicity [ 22 ] . From that starting point, QSAR has developed tremendously as a means of rapidly evaluating compounds for their predicted activity, prioritizing compounds for synthesis, and serving as a ch eaper alternative to costly biological assays [ 21 ] . As Verma et al. describe in their book, new evolutions in QSAR include expanded dimensionality such as, "3D-QSAR correlating activity with non-covalent interaction fi elds surrounding the molecules, 4D-QSAR additionally including ensemble of ligand confi gurations in 3D-QSAR, 5D-QSAR explicitly representing different induced-fi t models in 4D-QSAR" [ 21 ] .
Virtual screening , the technique introduced in "Stage 1" of this chapter, is a natural, automated extension of QSAR, as it uses the structural properties of compounds to predict binding ability. However, in this stage, we want to introduce another technique, fi ngerprint analysis, which also incorporates structural information about compounds.
Fingerprints refer to a grou p of variables that are collectively used to convey information about the structural features of a compound. PubChem generates a list of 881 binary substructure fi ngerprints for every chemical compound in their database [ 23 ] . The fi ngerprints are distributed into broad structural categories, including element counts, atom pairs, ring characteristics, atom neighborhoods, and SMARTS patterns. PubChem offers download of fi ngerprint information for any compound in their database. Subsequent use of Base64 decoding can convert the fi ngerprint into a list of 881 binary variables for each compound (Fig. 15.5 ) . We can then update our dataset to include a list of all of the compounds from the secondary screen (rows), which were each annotated with several variables: (1) the virtual binding score (from Stage 1) in Column 1, (2) the HTS "percent inhibition" score (from Stage 2) in Column 2, and (3) 881 binary fi ngerprint variables in Columns 3-883.
Stage IV: Topological Data Analysis
Using the results aggregated from the prior three stages, we now have a dataset that contains information about compounds with respect to their binding affi nity to the target, their empirical HTS assay result, and their granular structural features. In this stage, we will employ topological data analysis (TDA), a mathematical technique for studying shapes and preserving high-dimensionality, to create a similarity network of our compounds. TDA will allow us to visualize our library of compounds in a twodimensional network, whereby compounds (located in nodes) are connected to each other by a series of edges that refl ects their level of shared similarity (Fig. 15.6 ) . Therefore, two compounds that share several similar properties will appear closer together in the network, whereas two vastly different compounds will be farther apart. This network will make it simple to create subgroups or families of similar compounds, which can then be used to select the best compound leads.
We use Ayasdi Core (Ayasdi Inc., Menlo Park, CA) to create our TDA network of compounds. However, if access to Ayasdi Core is unavailable, alternative options include other TDA applications or employing weaker techniques such as K-means clustering to achieve somewhat similar results. We fi rst discuss the methodology as it relates to TDA and then explain a parallel process that can be employed with clustering algorithms.
A topological analysis is created with two types of parameters: a metric and a lens. A metric is a mathematical function used to m easure the similarity between two points in some space (usually between rows in the data). Bortezomib 881 binary substructure fingerprint: Fig. 15 .5 Schematic diagram depicting the translation of a 156-byte PubChem fi ngerprint into an 881 variable binary output, which will be used to describe the structural features of each compound greatly infl uences how the similarity of data points is assessed. Lenses are real valued functions on the data points. Lenses are used to create overlapping bins in the data set, where the bins are preimages under the lens of an interval. Overlapping families of intervals are used to create overlapping bins in the data. Metrics are used with lenses to construct the Ayasdi Core output. Further, multiple lenses can be used in each analysis. There are two user-determined parameters that are important in defi ning the bins. The fi rst is resolution , which determines the number of bins. Higher resolutions correspond to a greater number of bins and a fewer number of data points per bin. The second is gain , which determines the degree of overlap of the intervals. Increasing the gain increases the overlap between bins, such that they share more data points in common [ 10 -13 ] .
Once the bins are constructed, the software performs a clustering step within each bin. To do so, it uses single linkage clustering with a fi xed heuristic for the choice of the scale parameter [ 11 ] . Finally, the network is formed by creating a node for each cluster and connecting nodes if the corresponding clusters contain at least one data point in common. TDA also allows the user to identify the important factors or variables that distinguish two groups of nodes. To do so, it employs a nonparametric statistical test (Kolmogorov-Smirnov) in combination with the p-value (t-test).
The metric we will select for our analysis is Angle, and the lenses are L-Infi nity Centrality and Gaussian Density. The Angle metric computes the angle between two rows, by taking the inverse cosine of the dot product of the vectors. The L-infi nity Centrality lens calculates for each point x the maximal distance from x to any other data point in the dataset. Therefore, this lens is strongly correlated with density in normally distributed variables, but not as much in bimodal distributions. The Gaussian Density lens applies a kernel Gaussian density estimator by treating each row in Euclidean data space to estimate the density of that point.
The next choice with TDA algorithms is which columns in the data set you want to use for creation of the similarity network. The columns you choose will dictate the nature of the similarities. For our methods, we will use only the 881 structural fi ngerprint variables to create our network. The resulting graph will contain every compound in our library, connected to one another based on their structural fi ngerprint similarities (Fig. 15.6 ). Therefore, compounds in the same section of the network will inherently share a large set of common structural features. Ayasdi Core allows for further analysis by coloring the network by our variables of interest. In our technique, we will color our network fi rst by the vHTS score and then by the HTS score. The resulting pictures of the network provide a visual demonstration of which areas of the network contain compounds with the best binding energies and HTS results. Since we know the network was created based on structural fi ngerprint similarities, we can infer that those areas of the network must inherently contain certain structural features that may be related to their success.
After creating the network, we will fi rst examine it to understand its shape. Distinct "shapes" within the network represent families of compounds that share common properties, in this case structural features. These two-dimensional shapes instruct us of hidden multidimensional meaning about the structural features they share [ 11 , 12 ] . We will physically create these groups by drawing in boundaries between distinct shapes. Each enclosed group or family will then contain a set of compounds that we hypothesize shares similarities.
Next, we will annotate the network with the fi ndings from Stages 1 and 2 to begin the process of picking lead compounds. First, we will annotate the network by virtual binding score (Fig. 15.7 ) . Annotating refers to overlaying the network with a heat map (also referred to as "coloring") that refl ects each compound's value for a selected variable, in this case the virtual binding score. The annotations will depict which compounds within each family have the best virtual binding affi nity. We can then select the 3-5 best compounds by virtual affi nity score within each family as our leads. Second, we will annotate the network by the HTS assay result (Fig. 15.8 ) . Once again, we will select the 3-5 best compounds in each family, making note of which compounds were also chosen because of their virtual affi nity score. This method of choosing lead compounds after stratifying by structural families is advantageous because it ensures that a diverse set of leads are chosen (as they come from a diverse collection of structural families) and it is also more forgiving to certain compounds that may not have great absolute virtual binding or HTS scores, but may still turn out to be excellent drug choices. If we had simply identifi ed our hits by choosing the best 100 compounds by virtual binding score, we may unfairly bias ourselves towards one specifi c family of compounds that happen to be favored by that specifi c docking mechanism. As a result, we may overlook compounds with excellent in vivo potential that simply didn't have the features to make them successful in initial screens with virtual docking or in vitro HTS.
As a further refi nement step, we can use the annotation results to determine which 1-2 families of compounds performed best in both the virtual screen and HTS. With this knowledge, we can recursively add more compounds from those families to our initial library, as we know those families may contain certain important features. This method of expanding compound libraries around the hit compounds is becoming more prevalent in the pharmaceutical industry [ 24 ] .
If you do not have access to TDA, another process of lead identifi cation can be accomplished using k-means clustering, whereby you separate your compounds into k clusters based on shared properties, in this case the 881 PubChem structural fi ngerprints. Once the clusters are chosen, you can rank the compounds within each cluster fi rst by vHTS and next by HTS score. As was done above, select the 3-5 highest ranked compounds within each family for each scoring system. Instead of using a heat map or coloring mechanism to identify the best compounds, you will then numerically rank the compounds based on the value of their scores (vHTS and HTS).
To then accomplish the refi nement step of adding new compounds, rank the entire compound library by these two scores to determine which 1-2 families demonstrate the most consistent success. Recursively add new compounds from these families to the initial compound library. 
Conclusion
Our methodology described here combines virtual screening , high-throughput screening, structural fi ngerprints, and topological data analysis to more intelligently identify lead compounds from large compound libraries. Each of these individual techniques has several strengths but also shortcomings that can be mitigated by utilizing the techniques together. For example, virtual screening , although extremely fast and inexpensive, suffers from needing access to the 3D structure of the protein target and having some preexisting knowledge about its binding domains and tendencies. Conversely, HTS allows for comprehensive in vitro testing without any prior knowledge of the target, yet it often only tests the compound at one dose and in one type of assay, both of which are restrictions that could unfairly fi lter out otherwise excellent compounds. By combining both methods, we make use of their unique advantages without inheriting their shortcomings.
Researchers have already shown the benefi t of combining multiple types of methods in their work. For example, prior research has shown that a machinelearning model trained on HTS and chemical fi ngerprints performed similar or better than a model trained on either subset alone [ 24 ] . But even such approaches suffer from the same problem of selectively favoring compounds that perform well in the tested assays. Although this seems like a logical choice, it misses the mark because the ability of HTS, virtual screening , or fi ngerprints to predict in vivo drug success is far from perfect. There are many compounds that demonstrate excellent in vitro success but fail to have an effect in vivo, and vice versa [ 25 ] . And most of these shortcomings are because of pharmacokinetic and metabolic properties that are potentially secondary to their chemical structures. In other words, there are many compounds that aren't structurally suited for vHTS or HTS success, which are eliminated at an early stage in the drug discovery processes, even though they may have been excellent drugs. Similarly, certain structural features may predispose a certain family of compounds to receive very high scores in vHTS and HTS, which would lead to a disproportionately large number of compounds from that family advancing through the drug discovery pipeline. Thus, by using topological data analysis to fi rst create families of structural compounds, and then using our virtual screening and HTS results to choose the most promising compounds within each family, we ensure that a diversity of compounds are chosen for the next stage of the drug development cycle.
